Tadashi Koieyama

T‐0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor‐deficient mice

Y. Morikawa, D. Nakai, T. Inaba, 2003, FEBS letters.

Pravastatin sodium, an inhibitor of HMG-CoA reductase, decreases HDL cholesterol by transfer of cholesteryl ester from HDL to VLDL in Japanese white rabbits.

T. Koga, Tadashi Koieyama, T. Kikuchi, 2004, Journal of atherosclerosis and thrombosis.

Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.

N. Terasaka, Ayano Hiroshima, Tadashi Koieyama, 2011, Biochimica et biophysica acta.

LXRalpha regulates human CETP expression in vitro and in transgenic mice.

N. Terasaka, Ayano Hiroshima, Tadashi Koieyama, 2010, Atherosclerosis.

Effects of pravastatin sodium on mevalonate metabolism in common marmosets.

T. Koga, Tadashi Koieyama, T. Kikuchi, 2002, Journal of biochemistry.

ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.

T. Inaba, N. Terasaka, Tadashi Koieyama, 2007, Atherosclerosis.

Liver X receptor agonists inhibit tissue factor expression in macrophages

T. Fujiwara, T. Inaba, N. Terasaka, 2005, The FEBS journal.

Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.

N. Terasaka, Ayano Hiroshima, Tadashi Koieyama, 2011, Biochimica et biophysica acta.